Evidence map›Paper›PMID 40457031›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2025

A bioactive soluble recombinant mouse LIGHT promotes effective tumor immune cell infiltration delaying tumor growth.

Maria-Luisa Del Rio, Oscar-Mariano Nuero-Garcia, Giovanna Roncador, Raquel Garcimartín-Bailon, Juan-Carlos Cubria, Pascal Schneider, Jose-Ignacio Rodriguez-Barbosa

Abstract read
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maria-Luisa Del Rio *Transplantation Immunobiology and Immunotherapy Section, Institute of Molecular Biology, Genomics, and Proteomics (INBIOMIC), University of Leon, Leon, 24071, Spain. m.delrio@unileon.es.
Oscar-Mariano Nuero-GarciaMolecular Interactions Facility, Department of Cellular and Molecular Biosciences, Centro de Investigaciones Biológicas Margarita Salas, CIB-CSIC, Ramiro de Maeztu 9, 28040, Madrid, Spain.
Giovanna RoncadorMonoclonal Antibody Unit, Spanish National Cancer Research Centre, Madrid, Spain.
Raquel Garcimartín-BailonTransplantation Immunobiology and Immunotherapy Section, Institute of Molecular Biology, Genomics, and Proteomics (INBIOMIC), University of Leon, Leon, 24071, Spain.
Juan-Carlos CubriaDepartment of Biomedical Sciences, School of Veterinary Medicine, University of Leon, 24071, Leon, Spain.
Pascal SchneiderDepartment of Immunobiology, University of Lausanne, 1066, Epalinges, Switzerland.
Jose-Ignacio Rodriguez-Barbosa *Transplantation Immunobiology and Immunotherapy Section, Institute of Molecular Biology, Genomics, and Proteomics (INBIOMIC), University of Leon, Leon, 24071, Spain. ignacio.barbosa@unileon.es.ORCID http://orcid.org/0000-0001-7427-5654

Funding

Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España MCIN/ AEI/10.13039/501100011033Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España PID2022-136386OB-I00Swiss Re Foundation 310030-205196
6 · The paper itself

Abstract

The TNF family member LIGHT (TNFSF14) binds to two receptors, HVEM (TNFSFR14) and LTβR (TNFSFR3). HVEM functions as a costimulatory molecule, whereas LTβR is involved in the development of lymph nodes and ectopic tertiary lymphoid structures at chronic inflammation sites. The classical approach of fusing soluble recombinant proteins to the Fc fragment of IgG resulted in a functionally inactive Ig.mouse (m) LIGHT protein. However, in line with the fact that TNF family members cluster receptors as trimers, addition of a small homotrimeric domain (foldon) N-terminal of mLIGHT produced an Ig.Foldon-mLIGHT protein able to bind and engage HVEM and LTβR in a cell-based reporter bioassay. In the tumor model of B16.F10 melanoma cells implanted into syngeneic recipients, cells transduced with membrane-bound mLIGHT grew as aggressively as mock-transduced cells, but growth of tumors of B16.F10 cells expressing Ig.Foldon-mLIGHT was delayed and characterized by significant immune infiltration of dendritic cells and cytotoxic cells. This work unveils the potential of active soluble LIGHT, as a single agent, to recruit cytotoxic cells and dendritic cells at the tumor site to inhibit tumor growth. This effect may be further enhanced with immune checkpoint blockade therapies. KEY MESSAGES: The classical approach of fusing soluble recombinant proteins to the Fc fragment of IgG resulted in a functionally inactive Ig.mouse (m) LIGHT (TNFSF14) protein. The addition of a small homotrimeric domain (foldon) N-terminal of mouse LIGHT produces a proper folded bioactive mouse LIGHT recombinant protein. Constitutive intratumor expression of secreted Ig-Foldon-LIGHT, but not membrane LIGHT, delays tumor growth. Tumors secreting LIGHT, as a single agent, promote beneficial anti-tumor responses through the recruitment and infiltration of cytotoxic cells and dendritic cells.

Indexed as

Lymphocytes, Tumor-InfiltratingMelanoma, ExperimentalNeoplasmsTumor Necrosis Factor Ligand Superfamily Member 14AnimalsCell Line, TumorDendritic CellsFemaleHumansMiceMice, Inbred C57BLReceptors, Tumor Necrosis Factor, Member 14Recombinant Fusion ProteinsRecombinant ProteinsReceptors, Tumor Necrosis Factor, Member 14Recombinant Fusion ProteinsRecombinant ProteinsTnfsf14 protein, mouseTumor Necrosis Factor Ligand Superfamily Member 14B16.F10 melanomaHerpesvirus entry mediatorHVEMLIGHTLTβR

Identifiers

PMID40457031
PMCPMC12287161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.